Vascular Endothelial Growth Factor (VEGF) Inhibitor Prevalent and Incident Use

    Basic Details
    Date Posted
    Thursday, May 9, 2013
    Status
    Complete
    Medical Product
    bevacizumab
    sorafenib
    sunitinib
    thalidomide
    vascular endothelial growth factor (VEGF) inhibitor
    Description

    Modular program-based one-time assessment of the use of four different vascular endothelial growth factor (VEGF) inhibitors by generic drug name (bevacizumab, sorafenib, sunitinib, and thalidomide) in the Mini-Sentinel Distributed Database. A total of 3 different categories of counts were generated: (1) incident counts with respect to any of the four VEGF Inhibitors, (2) incident counts with respect to only the drug itself, and (3) prevalent counts (i.e., counts of users with at least one dispensing during the period of interest [2007-2010]). Modular programs are adaptable standardized programs. Results were generated using Modular Program 1; click here for more information. Programs were executed in August 2011.

    If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.

    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    CDER
    Time Period
    2007 - 2010
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)